A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Biopharma Insights


[Interview] A Company on the Cutting Edge of COVID-19 Vaccine Development

   by Andrii Buvailo    623
[Interview] A Company on the Cutting Edge of COVID-19 Vaccine Development

Recently, COVAXX announced it would soon enter human trials as the company is focused on rapidly developing a Multitope Peptide-based Vaccine (MPV) against SARS-CoV-2. While the biotech industry is now on a race to develop vaccines to curb COVID-19 pandemics, with several dozen players competing for the future market, COVAXX is a special case that can not be taken lightly.

Not only COVAXX’s new vaccine candidate is constructed off a commercially proven peptide-based vaccine platform by United Biomedical (UBI), a leader with a 30-year history in creating vaccines with over 500 million doses sold annually and 5 billion -- cumulatively in animal health indications for infectious disease that has demonstrated safety and efficacy. But it is also co-founded by two biotech “stars” of modern-day: Peter H. Diamandis, M.D., founder and executive chairman of XPRIZE, executive founder of Singularity University, and a dozen other tech companies, a popular science author; and Mei Mei Hu, co-founder of United Neuroscience, a member of Fortune “40 Under 40” and TIME “100 Next List”.

[Interview] A New Way To Work With Data In Life Sciences

   by Andrii Buvailo    215
[Interview] A New Way To Work With Data In Life Sciences

Founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker, Paradigm4 is not just any data analytics company in the Life Sciences. The organization is built on the decades of pioneering research in database design and possesses unique technological know-how in scientific data management and scalable computation. 

The firm has recently launched its REVEAL™: Single Cell app to offer biopharmaceutical developers the ability to break through the data wrangling and programming challenges associated with the analysis of large-scale, single-cell datasets. 

[Interview] Expediting Drug Discovery Through Advanced Machine Learning

   by Andrii Buvailo    256
[Interview] Expediting Drug Discovery Through Advanced Machine Learning

The application of next-generation data analytics tools, powered by machine learning and artificial intelligence (AI) components, has become a long-term strategic priority for most companies in the pharmaceutical and biotech industries. However, such systems have to make sure the organisational data is findable, accessible, interoperable, and reusable across different sub-systems, applications, departments, teams, and even companies. 

Aigenpulse, a technology company at the forefront of data management and analytics in the Life Science industry, has built a portfolio of tools for working with organisational research data at scale and accelerating the discovery and development of better targets and candidates using advanced machine learning technologies.

Clinical Research, Artificial Intelligence, and COVID-19

   by Raj Indupuri    378
Clinical Research, Artificial Intelligence, and COVID-19

How life sciences companies are reimagining trials during the biggest health crisis in a century

Whatever the world was like on March 15, it’s not like that now — and it probably won’t be for months or years. Everything from buying groceries to renewing a driver’s license is completely different from the way we did things just a few months ago. Clinical trials, like most medical activities, have been significantly affected as governments and pharmaceutical companies have pivoted to a single focus: combatting the novel coronavirus. At the same time, the rush to develop cures and vaccines for COVID-19 is condensing the review and approval process from years to months. This is where artificial intelligence (AI) can play a vital role in changing how clinical trials are conducted and how therapies are evaluated and tested.

A Leader in COVID-19 Vaccine Race, and the Bright Future for mRNA

   by Ivan Kondratov    482
A Leader in COVID-19 Vaccine Race, and the Bright Future for mRNA

Recently my favorite website ENDPOINTSNEWS published a rating of key players in the ongoing COVID-19 vaccine race. Compared to many vaccine developers with announced initiatives in this space, all the 28 organizations in the ENDPOINTSNEWS list stated at least preliminary positive results of their vaccine programs, and are firmly advancing them towards later stages of development. 

By the way, a notorious “Russian vaccine” by The Gamaleya Research Institute of Epidemiology and Microbiology also made its way to this list under the number 6, but I prefer not to touch upon this development. A lot has been said already about this story - to the point, and not so much. 

In this post I would rather talk about the number one in the list, a development undeservedly underrated by the media, which however might be the first to actually enter the global SARS-CoV2 vaccine market…